Literature DB >> 18370460

Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature.

W E Beyer1, A M Palache, A D Osterhaus.   

Abstract

Currently three different inactivated influenza vaccine types are available: whole virus (WV), split (SPL) and subunit (SU) vaccines. Physicians and patients at risk for influenza complications may wonder whether there are important differences between the vaccine types with respect to antibody induction (serology) and adverse effects (reactogenicity). A literature review (1975 to 1995) was performed to evaluate the serology and reactogenicity of SU vaccines in comparison with either split or whole virus vaccines. 22 publications with randomised allocation were identified describing a total of 5416 serological observations, 2858 observations of local reactions, and 2990 observations of systemic reactions. Subjects included those from all age groups from children to the elderly. Absolute protection and reaction rate differences (RD) were calculated for the comparisons SU vs SPL or SU vs WV vaccine. These were subjected to a method of meta-analysis, resulting in pooled rate differences and their 95% confidence intervals. With the exception of the comparison SU vs WV vaccine in subjects born after 1957 and unexposed to the reappearing H1N1 subtype after 1977, no evidence was found to suggest relevant differences in seroresponse among the three currently available inactivated influenza vaccine types. Although insufficient data were available in the meta-analysis for vaccines in children for whom specific recommendations concerning these vaccines exist, adverse events after administration of any of the three vaccine types were generally mild and transitory; however, SU vaccines were associated with a lower frequency of local and systemic reactions.

Entities:  

Year:  1998        PMID: 18370460     DOI: 10.2165/00044011-199815010-00001

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  66 in total

Review 1.  Antibody induction by influenza vaccines in the elderly: a review of the literature.

Authors:  W E Beyer; A M Palache; M Baljet; N Masurel
Journal:  Vaccine       Date:  1989-10       Impact factor: 3.641

2.  Human febrile response to influenza virus or its ether isolated hemagglutinins.

Authors:  F B Brandon; C D Barrett; A E Hook; G O Lease
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

3.  Comparative anti-influenza vaccination of some groups of the population with vaccines differing in virus purification level.

Authors:  L Brydak; W Gall; R Semkow
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1987       Impact factor: 4.291

4.  Inactivated influenza vaccines. 2. Laboratory indices of protection.

Authors:  W R Dowdle; M T Coleman; S R Mostow; H S Kaye; S C Schoenbaum
Journal:  Postgrad Med J       Date:  1973-03       Impact factor: 2.401

5.  Antigenic similarity of influenza A (H1N1) viruses from epidemics in 1977--1978 to "Scandinavian" strains isolated in epidemics of 1950--1951.

Authors:  A P Kendal; G R Noble; J J Skehel; W R Dowdle
Journal:  Virology       Date:  1978-09       Impact factor: 3.616

6.  Clinical reactions and antibody responses to influenza vaccines. A comparison of split or subunit vaccines in children and young adults.

Authors:  D I Bernstein; J D Cherry
Journal:  Am J Dis Child       Date:  1983-07

7.  A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity.

Authors:  A Clark; C W Potter; R Jennings; J P Nicholl; A F Langrick; G C Schild; J M Wood; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1983-06

8.  [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza. II. Neuraminidase inhibiting antibodies (author's transl)].

Authors:  J Werner; E K Kuwert; R Stegmaier; H Simböck
Journal:  Zentralbl Bakteriol A       Date:  1980-02

9.  Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.

Authors:  E K Kuwert; P G Höher; J Werner; N Scheiermann; O Thraenhart; B Müller; G Kleber
Journal:  Dev Biol Stand       Date:  1977 Jun 1-3

Review 10.  [Anti-influenza vaccination in children].

Authors:  A Battistini; R Ollari; L Dodi
Journal:  Pediatr Med Chir       Date:  1985 May-Jun
View more
  27 in total

1.  CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults.

Authors:  Aprille Seidel; David Smith; Edward Yung; Lia Aquino; Tumul Srivastava; Vinod Pullarkat; Ricardo Spielberger; Stephen J Forman; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-08       Impact factor: 5.742

2.  Response to influenza vaccine in people with non-protective HI antibody titers.

Authors:  Vincenzo Baldo; Tatjana Baldovin; Annarosa Floreani; Michele Minuzzo; Renzo Trivello
Journal:  Eur J Epidemiol       Date:  2006-11-03       Impact factor: 8.082

3.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

4.  Adult preferences for influenza vaccines with lower likelihood of side effects.

Authors:  Paul V Effler; Stephania Tomlin; Sarah Joyce; Donna B Mak
Journal:  Hum Vaccin Immunother       Date:  2013-11-04       Impact factor: 3.452

Review 5.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

6.  Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

Authors:  Renée A J van Boxtel; Pauline Verdijk; Otto J de Boer; Elly van Riet; Tjeert T Mensinga; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Influenza Hemagglutination-inhibition Antibody Titer as a Mediator of Vaccine-induced Protection for Influenza B.

Authors:  Benjamin J Cowling; Wey Wen Lim; Ranawaka A P M Perera; Vicky J Fang; Gabriel M Leung; J S Malik Peiris; Eric J Tchetgen Tchetgen
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

8.  Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models.

Authors:  Huayue Ye; Siyue Jia; Yuhui Zhang; Jingxin Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

Review 9.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

10.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.